Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Opella Healthcare UK Limited, trading as Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Mizolastine is a long-acting H1-antihistamine indicated for the symptomatic relief of seasonal allergic rhinoconjunctivitis (hay fever), perennial allergic rhinoconjunctivitis and urticaria.
Adults, including the elderly, and children 12 years of age and over: The recommended daily dose is one 10mg tablet.
In cases of overdose, general symptomatic surveillance with cardiac monitoring including QT interval and cardiac rhythm for at least 24 hours is recommended, along with standard measures to remove any unabsorbed medicinal product.
Studies in patients with renal insufficiency suggest that haemodialysis does not increase clearance of the medicinal product.
3 years in Aluminium/ (oPA/Aluminium/PVC) blisters.
2 years in Aluminium/PVC blisters.
3 years in securitainers.
Store in the original package.
Aluminium/ (oPA/Aluminium/PVC) blisters: This medicinal product does not require any special temperature storage conditions.
Aluminium/PVC blisters and securitainers: Do not store above 25°C.
Aluminium/(oPA/Aluminium/PVC) blisters: Packs of 4, 7, 10, 15, 20, 30, 50 or 100 tablets.
Aluminium/PVC blisters: Packs of 4, 7, 10, 15, 20, 30, 50 or 100 tablets.
Polypropylene tablet container with polyethylene caps: Packs of 4, 7, 10, 15, 20, 30, 50 or 100 tablets.
Not all pack sizes may be marketed.
Tablets should not be taken if they become discoloured.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.